Continued access to mitapivat for prior study participants
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study provides continued access to the drug mitapivat for people who have already been in a mitapativ study and are benefiting from it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in a previous study of the drug mitapivat.
- You must be getting a health benefit from mitapivat in that study, according to the study doctor.
- If you are a woman who could become pregnant, you must agree to use two forms of birth control or remain abstinent during the study and for 28 days after the last dose.
- You must not have a known allergy to mitapivat or any of its ingredients.
- You must not have any medical or mental health condition that would make it unsafe for you to join, be institutionalized by court order, or have a close relationship with the study team or sponsor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a daily pill called mitapivat can reduce the number of blood transfusions you need. It is for people with sickle cell disease who have had at least one transfusion in the past year and are not on regular transfusion therapy.
This study looks at the long-term safety and benefits of taking etavopivat for people with sickle cell disease or thalassaemia who have already been helped by it in a previous trial. It aims to see if staying on the treatment continues to be safe and effective.
This study provides continued access to avapritinib for people who have already been in a Blueprint Medicines trial and are still benefiting from the drug. It allows you to keep receiving treatment while staying monitored for safety.
This trial tests a drug called mitapivat (taken as a pill) to see if it can safely improve red blood cell health and reduce anemia symptoms in people with inherited red blood cell membrane disorders. It may help increase hemoglobin levels and relieve fatigue.
This study tests a study pill called mitapivat for children aged 1 to 17 with transfusion-dependent thalassemia. The goal is to see if mitapivat can reduce the need for blood transfusions and improve blood counts.
This study tests a medicine called mitapivat in children ages 1–17 with thalassemia who don't need frequent blood transfusions. The medicine may help their bodies make more healthy red blood cells and reduce anemia symptoms.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.